Portfolio Analytics Lead
About the job
- A Bachelor's degree in Business, Economics, Statistics, Mathematics, Physical Sciences, or a related field is a plus; an MBA or graduate-level degree is preferred.
- Seven or more years of work experience with a Bachelor's degree, five or more years with a Master's degree, or three or more years with a PhD or JD; pharmaceutical or biotech industry experience (commercial or clinical) and/or management consulting experience is preferred.
- Deep expertise in at least one of the following areas: Patient Insights, Investigator Insights, Forecasting, Competitive Intelligence, Data Analytics, Statistics, Advanced Data Analytics, Resourcing, Information Visualization, or Data Science.
- Demonstrated experience translating data into insights and creating compelling narratives.
- Understanding of the advantages and limitations of different analytical approaches.
- Considerable experience applying exploratory and confirmatory data analysis techniques that inform business decisions.
- Experience with scripting, statistical and programming languages, and analytical tools such as Python, R, SQL, MATLAB, SAS, Google Analytics, or Adobe Analytics is preferred.
- Ability to examine data or content autonomously or semi-autonomously.
- Demonstrated use of sophisticated techniques, tools, and languages beyond traditional data analysis to discover deeper insights, make predictions, or generate recommendations.
- Experience acting as a strategic thought partner to teams and an entrepreneurial mindset to transform the use of data and analytics to enable decisions and accelerate medicine delivery.
- Track record of working effectively in a matrix environment with international team members from scientific, business, and operational backgrounds, using influence without authority.
- Expertise in standard analysis and presentation software, including Excel and PowerPoint.
- Ability to merge datasets from disparate sources and report findings in a variety of formats and mediums.
- Experience managing outside vendors is preferred.
- Demonstrated comfort in an entrepreneurial environment and a strong sense of responsibility.
- Ability to work effectively in a fluid, cross-functional, global matrix environment and adapt to competing priorities.
- Strong interpersonal skills and a consultative mindset to develop partnerships.
- Ability to break down complex problems, manage uncertainty, and understand and anticipate interdependencies.
- Ability to ask thought-provoking questions to connect information and ideas.
- Ability to present insights objectively and guide decision-making by pairing sound analytics with storytelling.
- Motivation to continuously improve performance and achieve outcomes.
- Ability to manage through change.
- Commitment to elevating data analytics in decision-making and building data-literate communities.
- Persuasive written and verbal communication skills, including the ability to communicate complex ideas.
- Strong attention to detail.
- Work with Clinical Operations Disease Area Communities, Clinical Operations Portfolio Enabling Communities, Franchise Leads, Study Management and Country Leaders, Study Management Teams, Late Stage Portfolio Committee stakeholders, and Lifecycle Teams to understand business needs, priorities, and immediate work scope.
- Deliver integrated insights and analytics, trade-off analyses, and risk assessments to optimize patient recruitment strategies, country footprint, and clinical site selection for ongoing and planned clinical trials.
- Partner with stakeholders to assess the health of the clinical-trial portfolio and identify opportunities to accelerate study delivery and product launches.
- Increase the sophistication and application of advanced analytics methods, including predictive modeling, machine learning, and scalable prototypes, to measure study performance and guide portfolio-level decisions efficiently.
- Create and manage tools with current industry information to build accurate short- and long-term forecasts.
- Work with team members to incorporate insights from primary and secondary data and continuously improve forecasting methods and accuracy.
- Communicate how trial design elements, country and site selection, competitor activities, and new engagement tactics affect clinical-trial recruitment and retention forecasts.
- Provide the team with technical and analytical expertise through secondary data analytics.
- Apply analytical and statistical methods, using multiple data sources and technical tools or languages, to answer business questions.
- Monitor and assess the effectiveness of enrollment and engagement efforts, projects, and practices, and identify opportunities to optimize investment value.
- Support identification of appropriate sites and countries for trial placement.
- Act as a subject matter expert for applicable advanced analytical methodologies, programs, and projects.
- Collaborate with cross-functional teams to develop solutions, build alignment, deliver business insights, and engage stakeholders to support better decision-making.
- Share perspectives and insights to elevate team thinking, develop a balanced view, and communicate trade-offs.
- Link individual responsibilities to broader organizational goals and focus on outcomes that provide the greatest business value.
- Demonstrate self-accountability and integrity.
- Engage stakeholders to understand and diagnose business problems and recommend appropriate courses of action.
- Identify opportunities for continuous improvement and engage managers and peers for coaching, assistance, and advocacy.
- Stay current with and adopt relevant emerging methodologies, tools, and applications to ensure fit-for-purpose, impactful approaches.
- Act as a thought partner and advisor to relevant teams and stakeholders, and establish opportunities for peer mentorship.
- Participate in cross-functional communities, networks, and knowledge-sharing bodies to enable broader and more effective use of insights and analytics in decision-making.
- Acquire, aggregate, and curate data and information.
- Portfolio management experience is highly desirable.
- Experience with various forecasting methods and techniques is strongly preferred.
About the company
Genentech is a biotechnology company focused on researching and developing medicines and therapies to address unmet medical needs. It uses large-scale R&D, with about 13,500 employees and 40 approved medicines; it develops biologics and other therapies marketed through healthcare providers, generating revenue from sales. It differentiates itself with a large patent portfolio (around 20,000 patents) and multiple FDA Breakthrough Therapy Designations, along with a patient-centric approach that weighs access and affordability. Its goal is to advance medical science and deliver high-quality, effective therapies that improve patient health and support the broader medical community.
Company Size
10,001+
Company Stage
Grant
Total Funding
$47.8M
Headquarters
San Francisco, California
Founded
1976
Get referred to Genentech
See people who can refer or advise you
Simplify's Take
What believers are saying
- Hillsboro broke ground September 28, 2026 on a $750 million device fill-finish plant.
- The project adds 250 jobs and strengthens U.S. supply for oncology, neurology, immunology.
- Roche opened Boston's CVRM Innovation Center on September 17, 2026, expanding discovery capacity.
What critics are saying
- September 2026 layoffs cut 265 South San Francisco jobs, ending a 40-year plant.
- June and July 2026 cuts removed 103 gRED roles, signaling continuing research retrenchment.
- Vabysmo concentration leaves Genentech vulnerable to a retinal franchise reversal by 2027.
What makes Genentech unique
- Roche-backed Genentech pairs drug discovery with manufacturing, diagnostics, and global commercialization at scale.
- Vabysmo delivered real-world eye-disease data on September 30, 2026 across 28 countries.
- The September 24, 2026 Earendil deal shows Genentech still commands elite biotech partners.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Performance Bonus
Relocation Assistance
Growth & Insights and Company News
6 month growth
-3%1 year growth
-3%2 year growth
-3%The FDA has approved Genentech's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III deficient DNA mismatch repair colon cancer. This marks Tecentriq's twelfth indication in the US. The approval follows results from the Phase III ATOMIC study, published in The New England Journal of Medicine. The trial showed Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival was 86% with Tecentriq combined with mFOLFOX6, versus 76% with mFOLFOX6 alone. Nearly 25% of colon cancers are diagnosed at stage III. Almost one in three patients with stage III colon cancer experience recurrence within five years. This represents the first approved adjuvant immunotherapy regimen for this patient population.
Alector licenses Parkinson's drug program to Genentech for $1.27B. On Oct 7, 2026 Alector has entered into an exclusive global licensing agreement with Genentech, a member of the Roche Group, to develop and commercialize AL050, an investigational therapy designed to treat a key cause of neurodegeneration linked to Parkinson's disease. Under the agreement, Genentech will receive worldwide rights to AL050, which is designed to address deficiencies in glucocerebrosidase (GCase), an enzyme linked to Parkinson's disease, particularly in people carrying mutations in the GBA1 gene. Alector will receive $100 million upfront from Genentech and could receive up to an additional $1.17 billion in development, regulatory and commercial milestone payments. The company will also be eligible for tiered royalties based on net sales. AL050 combines an engineered version of the GCase enzyme with Alector's proprietary Alector Brain Carrier (ABC) technology. The approach is designed to help the therapy cross the blood-brain barrier and reach the brain, where GCase deficiency can cause harmful lipids to build up in nerve cells. The therapy is intended to break down glucosylsphingosine and glucosylceramide, two lipids that can accumulate when GCase activity is reduced. Alector believes reducing this buildup could help improve cell function and potentially slow the progression of Parkinson's disease. GCase deficiency is increasingly being studied as an important driver of Parkinson's disease. People with GBA1 mutations are at higher risk of developing the disease, although GCase-related mechanisms may also play a role in patients without these mutations. Under the partnership, Genentech will take responsibility for the development, regulatory work, manufacturing and commercialization of AL050 across all potential indications. Alector will retain ownership of its ABC technology and continue using the platform in its wholly owned pipeline. Alector CEO Arnon Rosenthal said the company designed AL050 to address two major challenges in treating GCase deficiency: developing an enzyme with strong and lasting activity and delivering it effectively into the brain. The deal also gives Alector additional resources to advance its other programs. The company said the partnership extends its cash runway into 2029. Alector plans to use these resources to advance its subcutaneously delivered, brain-enabled anti-Aβ antibody program toward multi-cohort clinical data in Alzheimer's disease. The company also plans to move its brain-enabled tau siRNA and alpha-synuclein siRNA programs through IND-enabling studies and toward regulatory filings. The collaboration marks another major step in Genentech's efforts to develop new treatments for Parkinson's disease, while giving Alector the financial support to continue developing therapies targeting neurodegenerative diseases.
Genentech AI leader richard Bonneau departs amid talent war. This post contains affiliate links, and I will be compensated if you make a purchase after clicking on my links, at no cost to you. The artificial intelligence sector within the pharmaceutical industry has experienced another major shakeup following the departure of a key executive. Richard Bonneau, a prominent AI leader who spearheaded critical computational biology initiatives, has officially left Genentech. This high-profile exit highlights an ongoing corporate tug-of-war for elite technological expertise. Major drugmakers are aggressively competing to secure specialized minds who can seamlessly integrate advanced machine learning into modern research and development pipelines. Table of Contents The battle for elite computational talent. Traditional pharmaceutical giants face unique hurdles when trying to retain top-tier tech leadership in a rapidly evolving marketplace. Nimble startups and heavily funded biotechnology enterprises frequently lure innovators away with massive resources and flexible environments. For those fascinated by how technology reshapes specialized fields, keeping pace with these shifts requires continuous learning. Exploring recent optics articles or reviewing breaking developments can offer broader perspectives on how technical industries adapt to rapid transformation. The impact on modern drug discovery pipelines. Genentech has channeled substantial investments into machine learning to revolutionize how new treatments are discovered and developed. Although Bonneau's future destination remains undisclosed, the corporation is expected to press forward with its core artificial intelligence strategy. The broader life sciences landscape continues to treat computational expertise as an absolute premium asset. Observers expect the fierce competition for visionary leaders to persist as data-driven methodologies redefine the boundaries of modern science. Additional Reading:
Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion. Published on 10/05/2026 at 08:08 am EDT - Modified on 10/05/2026 at 08:16 am EDT Oct 5 (Reuters) - Swiss drugmaker Roche will pay up to $1.27 billion to license Alector's experimental treatment for Parkinson's disease, the US biotech said on Monday, sending its shares surging 72% in premarket trading. Genentech, a unit of Roche, will pay Alector $100 million upfront and up to $1.17 billion more if the treatment reaches development, regulatory and sales targets. Alector is also eligible for royalties. Here are some details: o The agreement grants Genentech exclusive worldwide rights to develop, make and sell AL050, an experimental treatment designed to address a lack of an enzyme linked to Parkinson's disease o Genentech will be responsible for development, regulatory submissions, manufacturing and commercialization of the treatment o AL050 is an enzyme replacement therapy designed to address the deficiency of the GCase enzyme that leads to the buildup of certain fats and a higher risk of Parkinson's disease o The deal is the latest in a series of licensing agreements by Roche as it works to expand its drug pipeline o In June, Roche agreed a licensing and collaboration deal with Nurix Therapeutics worth up to $2.3 billion for a blood cancer drug (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Sahal Muhammed) (C) Reuters - 2026
Alector enters global license agreement with Genentech for brain penetrant GCase Enzyme Replacement Therapy for Parkinson's Disease and other neurodegenerative diseases. October 05, 2026 07:00 ET | Source: Alector, Inc. Alector grants Genentech exclusive rights to develop and commercialize AL050, an investigational GCase Enzyme Replacement Therapy (ERT) enabled by Alector Brain Carrier (ABC), Alector's proprietary blood-brain barrier delivery platform Alector to receive $100 million upfront payment, with potential for up to $1.17 billion in additional milestone payments, as well as tiered royalties on net sales SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) - Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it has entered into an exclusive global licensing agreement with Genentech, a member of the Roche Group, granting Genentech worldwide rights to develop and commercialize Alector's AL050 program, its brain-penetrant engineered glucocerebrosidase (GCase) ERT. AL050 is designed to address GCase deficiency, a driver of neurodegeneration in Parkinson's Disease that is most pronounced in - but not limited to - carriers of GBA1 mutations. It combines an Alector-engineered GCase, optimized for greater enzymatic activity and a longer half-life, with Alector's ABC, which is designed to transport therapeutics across the blood-brain barrier. Delivered into the brain, the enzyme is intended to break down glucosylsphingosine and glucosylceramide, lipids that accumulate in neurons and other brain cells upon GCase deficiency and contribute to neurodegeneration, with the aim of reducing cellular dysfunction and slowing disease progression. "Deficient GCase activity is increasingly recognized as a contributor to Parkinson's Disease, and there is still no approved therapy that addresses the underlying enzyme deficiency," said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. "The challenge in treating GCase deficiency is twofold: engineering an enzyme with optimal activity and durability and successfully delivering it to the brain. AL050 addresses this by pairing an engineered GCase enzyme with our proprietary Alector Brain Carrier technology designed to cross the blood-brain barrier. Genentech's long-standing commitment to Parkinson's Disease makes them an ideal partner as this program moves toward the clinic". "Parkinson's Disease is one of the fastest-growing neurological conditions worldwide," said Boris L. Zaïtra, Head of Roche Corporate Business Development. "By partnering with companies such as Alector we aim to delay or halt the progression of Parkinson's so patients maintain and prolong their independence." Under the terms of the agreement, Alector will receive an upfront payment of $100 million and is also eligible to receive additional payments of up to $1.17 billion upon the achievement of development, regulatory, and commercial milestones. Alector is also eligible for tiered royalties on net sales. Under the collaboration, Genentech will be responsible for development, regulatory, manufacturing, and commercialization across all indications. Alector retains ownership of ABC and full rights to apply the platform across its wholly owned pipeline. "This partnership extends our cash runway into 2029, providing resources to advance our fully active, subcutaneously delivered, brain-enabled anti-Aβ antibody to multi-cohort clinical data in Alzheimer's patients, and move our subcutaneously delivered, brain-enabled Tau siRNA and alpha- synuclein siRNA programs through IND-enabling studies and to IND filings," said Dr. Rosenthal. Alector R&D Webinar on Wholly Owned Pipeline Alector will host a scientific webinar on Tuesday, October 13th, 2026, at 8:00 a.m. PT, focused on AL137, its brain-enabled anti-Aβ antibody; AL164, its tau siRNA program; and AL062, its alpha-synuclein siRNA program. Registration and webcast information will be available on the Events and Presentations page of the Alector corporate website. About Alector Alector is a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector's product candidates seek to treat a range of indications, such as Alzheimer's disease and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being applied to its preclinical and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding our business plans, business strategy, product candidates, research and preclinical pipeline, blood-brain barrier technology platform, planned and ongoing preclinical studies, planned clinical trials, expected milestones, expectations of our collaborations, and financial and cash guidance. Such statements are subject to numerous risks and uncertainties, including but not limited to risks and uncertainties as set forth in Alector's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, with the Securities and Exchange Commission (SEC), as well as the other documents Alector files from time to time with the SEC. These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alector's forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law. Alector Contacts Argot Partners (media) David Rosen 646-461-6387 [email protected] Argot Partners (investors) Laura Perry [email protected]